◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PMVP

PMV Pharmaceuticals, Inc. (PMVP) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

PMV Pharmaceuticals, Inc. (PMVP) operates in the Biotechnology industry and is headquartered in Princeton, United States with about 54 employees. Its market capitalization is roughly $71 million. In the fiscal year ended 2025-12-31, PMVP reported $0M in revenue and ($78M) in net income.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.

Interactive charts & full statements →

PMVP Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($86M)($85M)($80M)($77M)
Net Income($78M)($59M)($69M)($73M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PMVP Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($19M)($19M)($22M)($23M)($22M)
Net Income($18M)($18M)($21M)($21M)($17M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PMVP Free Cash Flow History

PMVP Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$117M$191M$252M$270M
Total Liabilities$12M$15M$26M$24M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PMVP viewer.

Other Companies in Biotechnology

← PMTSAll stocksPN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.